34671210|t|Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/beta-catenin-Cyp2e1 Signaling.
34671210|a|Background: Nonalcoholic fatty liver disease (NAFLD) is a serious threat to human health worldwide, with a high genetic susceptibility. Rs2302685, a functional germline variant of LRP6, has been recently found to associate with NAFLD risk. This study was aimed to clarify the underlying mechanism associated with rs2302685 risk and its impact on pharmacotherapy in treatment of NAFLD. Methods: Venous blood samples were collected from NAFLD and non-NAFLD patients for SNP genotyping by using mass spectrometry. The Lrp6-floxdel mouse (Lrp6(+/-)) was generated to model the partial function associated with human rs2302685. The liver injury and therapeutic effects of silibinin were compared between Lrp6(+/-) and Lrp6(+/+) mice received a methionine-choline deficient (MCD) diet or normal diet. The effect of Lrp6 functional alteration on Wnt/beta-catenin-Cyp2e1 signaling activities was evaluated by a series of cellular and molecular assays. Results: The T allele of LRP6 rs2302685 was confirmed to associate with a higher risk of NAFLD in human subjects. The carriers of rs2302685 had reduced level of AST and ALT as compared with the noncarriers. The Lrp6(+/-) mice exhibited a less severe liver injury induced by MCD but a reduced response to the treatment of silibinin in comparison to the Lrp6(+/+) mice, suggesting Lrp6 as a target of silibinin. Wnt/beta-catenin-Cyp2e1 signaling together with ROS generation could be exacerbated by the overexpression of Lrp6, while decreased in response to Lrp6 siRNA or silibinin treatment under NAFLD modeling. Conclusions: The Lrp6 function affects individual susceptibility to NAFLD and the therapeutic effect of silibinin through the Wnt/beta-catenin-Cyp2e1 signaling pathway. The present work has provided an underlying mechanism for human individual susceptibility to NAFLD associated with Lrp6 polymorphisms as well as a rationale for the effective use of silibinin in NAFLD patients.
34671210	0	4	Lrp6	Gene	16974
34671210	51	83	Nonalcoholic Fatty Liver Disease	Disease	MESH:D065626
34671210	127	139	beta-catenin	Gene	12387
34671210	140	146	Cyp2e1	Gene	13106
34671210	170	202	Nonalcoholic fatty liver disease	Disease	MESH:D065626
34671210	204	209	NAFLD	Disease	MESH:D065626
34671210	234	239	human	Species	9606
34671210	294	303	Rs2302685	SNP	tmVar:Rs2302685;VariantGroup:0;CorrespondingGene:4040;RS#:2302685;CorrespondingSpecies:9606
34671210	338	342	LRP6	Gene	4040
34671210	386	391	NAFLD	Disease	MESH:D065626
34671210	471	480	rs2302685	SNP	tmVar:rs2302685;VariantGroup:0;CorrespondingGene:4040;RS#:2302685;CorrespondingSpecies:9606
34671210	536	541	NAFLD	Disease	MESH:D065626
34671210	593	598	NAFLD	Disease	MESH:D065626
34671210	607	612	NAFLD	Disease	MESH:D065626
34671210	613	621	patients	Species	9606
34671210	673	677	Lrp6	Gene	16974
34671210	686	691	mouse	Species	10090
34671210	693	697	Lrp6	Gene	16974
34671210	764	769	human	Species	9606
34671210	770	779	rs2302685	SNP	tmVar:rs2302685;VariantGroup:0;CorrespondingGene:4040;RS#:2302685;CorrespondingSpecies:9606
34671210	785	797	liver injury	Disease	MESH:D017093
34671210	825	834	silibinin	Chemical	MESH:D000077385
34671210	857	861	Lrp6	Gene	16974
34671210	871	875	Lrp6	Gene	16974
34671210	881	885	mice	Species	10090
34671210	897	907	methionine	Chemical	MESH:D008715
34671210	908	915	choline	Chemical	MESH:D002794
34671210	967	971	Lrp6	Gene	16974
34671210	1001	1013	beta-catenin	Gene	12387
34671210	1014	1020	Cyp2e1	Gene	13106
34671210	1127	1131	LRP6	Gene	4040
34671210	1132	1141	rs2302685	SNP	tmVar:rs2302685;VariantGroup:0;CorrespondingGene:4040;RS#:2302685;CorrespondingSpecies:9606
34671210	1191	1196	NAFLD	Disease	MESH:D065626
34671210	1200	1205	human	Species	9606
34671210	1232	1241	rs2302685	SNP	tmVar:rs2302685;VariantGroup:0;CorrespondingGene:4040;RS#:2302685;CorrespondingSpecies:9606
34671210	1263	1266	AST	Gene	26503
34671210	1313	1317	Lrp6	Gene	16974
34671210	1323	1327	mice	Species	10090
34671210	1352	1364	liver injury	Disease	MESH:D017093
34671210	1423	1432	silibinin	Chemical	MESH:D000077385
34671210	1454	1458	Lrp6	Gene	16974
34671210	1464	1468	mice	Species	10090
34671210	1481	1485	Lrp6	Gene	16974
34671210	1501	1510	silibinin	Chemical	MESH:D000077385
34671210	1516	1528	beta-catenin	Gene	12387
34671210	1529	1535	Cyp2e1	Gene	13106
34671210	1560	1563	ROS	Chemical	-
34671210	1621	1625	Lrp6	Gene	16974
34671210	1658	1662	Lrp6	Gene	16974
34671210	1672	1681	silibinin	Chemical	MESH:D000077385
34671210	1698	1703	NAFLD	Disease	MESH:D065626
34671210	1731	1735	Lrp6	Gene	16974
34671210	1782	1787	NAFLD	Disease	MESH:D065626
34671210	1818	1827	silibinin	Chemical	MESH:D000077385
34671210	1844	1856	beta-catenin	Gene	12387
34671210	1857	1863	Cyp2e1	Gene	13106
34671210	1941	1946	human	Species	9606
34671210	1976	1981	NAFLD	Disease	MESH:D065626
34671210	1998	2002	Lrp6	Gene	4040
34671210	2065	2074	silibinin	Chemical	MESH:D000077385
34671210	2078	2083	NAFLD	Disease	MESH:D065626
34671210	2084	2092	patients	Species	9606
34671210	Negative_Correlation	MESH:D000077385	MESH:D017093
34671210	Association	26503	4040
34671210	Association	13106	16974
34671210	Positive_Correlation	MESH:D065626	RS#:2302685;CorrespondingGene:4040
34671210	Association	MESH:D065626	16974
34671210	Association	MESH:D000077385	16974
34671210	Association	MESH:D065626	12387
34671210	Association	12387	13106
34671210	Association	12387	16974
34671210	Association	MESH:D065626	4040
34671210	Association	MESH:D000077385	13106
34671210	Association	MESH:D000077385	12387
34671210	Association	MESH:D017093	16974
34671210	Association	MESH:D065626	4040

